5. Accounts Payable	3 Months Ended
Mar. 31, 2026
Payables and Accruals [Abstract]
5. Accounts Payable	5. Accounts Payable As of March 31, 2026, current liabilities included accounts payable of $5.2 million, comprised primarily of expenses related to clinical trial expenses of $3.3 million, legal and patent fees of $0.6 million, drug manufacturing development and testing services of $0.4 million, public company registration and filing fees of $0.2 million and professional and consulting fees of $0.2 million. As of December 31, 2025, current liabilities included accounts payable of $4.9 million, comprised primarily of expenses related to the Company’s clinical trials of $3.3 million, drug manufacturing development and testing services of $0.4 million and legal and patent fees of $0.6 million.

5. Accounts Payable

3 Months Ended

Mar. 31, 2026

5. Accounts Payable

As of March 31, 2026, current liabilities included accounts payable of $5.2 million, comprised primarily of expenses related to clinical trial expenses of $3.3 million, legal and patent fees of $0.6 million, drug manufacturing development and testing services of $0.4 million, public company registration and filing fees of $0.2 million and professional and consulting fees of $0.2 million. As of December 31, 2025, current liabilities included accounts payable of $4.9 million, comprised primarily of expenses related to the Company’s clinical trials of $3.3 million, drug manufacturing development and testing services of $0.4 million and legal and patent fees of $0.6 million.